Using a new definition that includes waist-based measurements, the team found that more than 75% of adults may meet criteria ...

Wegovy pill, the first ever non-injectable GLP-1 for obesity, from drugmaker Novo Nordisk. Competitors like Eli Lilly are ...

The retrospective study could not determine whether some patients were more likely than others to keep off the weight.

The health-care corner of the US equity market has traditionally been viewed as defensive, thanks to steady growth and healthy dividend yields among the industry’s stalwarts. That narrative is ...

Arrowhead Pharmaceuticals has reported early-phase data on a pair of gene silencing drug candidates in obesity, posting ...

Over 27 percent of adults worldwide with obesity qualify for GLP-1 weight loss medicines but access remains unequal.

"Food noise" is the buzz in the battle against obesity. GLP1 injectables don't just decrease appetite, but also quiet "food ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...

Arrowhead Pharmaceuticals said Tuesday that its gene-silencing candidates helped people with obesity lose fat.

The consumer champion is now calling on the government to introduce a mandatory front-of-pack nutrition labelling scheme. It ...

Obesity is a complex, chronic condition that affects millions of Americans, and treating it often requires more than just ...

Brian Lian founded publicly traded Viking Therapeutics to focus on metabolic diseases. With obesity drugs in development and ...